Jill E. Hunter
Newcastle Upon Tyne, ENG NE24HH, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
c-Rel-dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis.
Journal: Hepatology (Baltimore, Md.)
Published: May 23, 2022
Mutation of the RelA(p65) Thr505 phosphosite disrupts the DNA replication stress response leading to CHK1 inhibitor resistance.
Journal: The Biochemical journal
Published: February 28, 2022
Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathway.
Journal: The Biochemical journal
Published: February 28, 2022
Claspin haploinsufficiency leads to defects in fertility, hyperplasia and an increased oncogenic potential.
Journal: The Biochemical journal
Published: February 24, 2022
Centrosome dysfunction associated with somatic expression of the synaptonemal complex protein TEX12.
Centrosome dysfunction associated with somatic expression of the synaptonemal complex protein TEX12.
Journal: Communications biology
Published: November 04, 2020
Increased migration and motility in XIAP-null cells mediated by the C-RAF protein kinase.
Journal: Scientific reports
Published: July 04, 2019
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia.
Journal: Oncotarget
Published: August 07, 2015
c-Rel and its many roles in cancer: an old story with new twists.
Journal: British journal of cancer
Published: July 08, 2015
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Journal: Oncotarget
Published: April 30, 2015
Last Updated: 09/26/2026